Zepbound: what it is, who it's for, and how people pay for it
How this page is paid for: Some links here are partner links. If you start care through one, the provider may pay LongevityGLP1 a fee, and your monthly price stays the same. How we make money
The short answer
Zepbound is Eli Lilly's once-weekly tirzepatide injection, approved for adults with obesity (or overweight plus a weight-related condition) to lose weight and keep it off, and for obstructive sleep apnea with obesity. It contains the same drug as Mounjaro. LillyDirect sells it for cash starting at $299 a month.
Definition
Zepbound is a once-weekly tirzepatide injection made by Eli Lilly. FDA approved it on November 8, 2023 for chronic weight management and on December 20, 2024 for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro contains the same drug for type 2 diabetes.
Key facts
| Fact | Detail |
|---|---|
| Active ingredient | Tirzepatide, a GIP and GLP-1 receptor agonist |
| Maker | Eli Lilly |
| First FDA approval | November 8, 2023 (NDA 217806)[2] |
| Approved for | Weight reduction and maintenance in adults with obesity, or overweight plus a weight-related condition; moderate to severe obstructive sleep apnea with obesity[1] |
| Forms | Single-dose pen, single-dose vial, multi-dose vial and KwikPen (4 doses each for the last two) |
| Boxed warning | Thyroid C-cell tumors in rodents |
| Self-pay (LillyDirect) | From $299 a month (vial or KwikPen)[6] |
| Prescription | Required |
Zepbound is the weight-loss label of tirzepatide, the same molecule Eli Lilly sells as Mounjaro for type 2 diabetes. What sets Zepbound apart in 2026 isn't only the trial results. It's that Lilly sells it directly for cash, so a prescription and a few hundred dollars a month are enough to start, with or without insurance.
Zepbound is tirzepatide for weight and sleep apnea
Zepbound is the weight-management and sleep-apnea brand of tirzepatide, Eli Lilly's weekly injection that acts on two hormone receptors, GIP and GLP-1. Most older drugs in this class act on GLP-1 alone. Tirzepatide was the first approved drug to hit both.
The label explains the weight effect in plain terms. GLP-1 “is a physiological regulator of appetite and caloric intake,” and nonclinical studies suggest GIP adds to that [1]. Tirzepatide “decreases calorie intake,” the effect is “likely mediated by affecting appetite,” and it “lowers body weight with greater fat mass loss than lean mass loss.” It also slows stomach emptying, most after the first dose. The full mechanism, for both brands, is on our tirzepatide page.
Zepbound has two approved uses: weight and sleep apnea
The Zepbound label lists two uses. The first is reducing excess weight and keeping it off in adults with obesity, or with overweight plus at least one weight-related condition. The second is treating moderate to severe obstructive sleep apnea in adults with obesity [1]. When FDA approved the sleep apnea use on December 20, 2024, it called Zepbound the first medication for that condition [3].
| Date | What changed | Trial behind it | Source |
|---|---|---|---|
| November 8, 2023 | Approved for chronic weight management | SURMOUNT program | FDA [2] |
| December 20, 2024 | Approved for obstructive sleep apnea in adults with obesity | SURMOUNT-OSA [11] | FDA [3] |
| August 26, 2026 | Heart-outcome trial data added to the label (not a new use) | SURPASS-CVOT [13] | FDA letter [4] |
Is Zepbound for diabetes or weight loss? Weight loss and sleep apnea. Zepbound isn't approved to treat type 2 diabetes; that's Mounjaro's label. People with type 2 diabetes can still be prescribed Zepbound for weight, and the label warns about low blood sugar in that group. Our Zepbound vs Mounjaro comparison shows where the two labels split.
Zepbound is for adults with a BMI of 30, or 27 with a weight-related condition
In practice, the weight label covers two groups. The trials defined obesity as a BMI of 30 or more. They also enrolled adults with a BMI of 27 to 30 plus a weight-related condition, such as high blood pressure, abnormal cholesterol, sleep apnea or heart disease [1]. The sleep apnea use is for adults with obesity and moderate to severe apnea.
Some people shouldn't take it. The label rules Zepbound out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and for anyone who has had a serious allergic reaction to tirzepatide. It says it may cause fetal harm, so it isn't used in pregnancy. It isn't approved for children, and the label doesn't recommend it for people with severe gastroparesis.
What about people with type 2 diabetes? They were studied too. In the label's Study 2, adults with type 2 diabetes and a BMI of 27 or more lost less weight than people without diabetes, and low blood sugar was more common: 4.2% on Zepbound vs 1.3% on placebo [1]. If you take insulin or a sulfonylurea, your prescriber may lower that dose when you start.
In trials, people lost about 15% to 21% of body weight
In SURMOUNT-1, adults with obesity and no diabetes lost 15.0%, 19.5% and 20.9% of their weight on 5, 10 and 15 mg over 72 weeks, against 3.1% on placebo [9]. Half or more of people on the two higher doses lost at least 20% of their weight.
| Trial | Who was studied | Result | Funded by |
|---|---|---|---|
| SURMOUNT-1 [9] | 2,539 adults with obesity, no diabetes, 72 weeks | Weight −15.0% to −20.9% vs −3.1% on placebo | Eli Lilly |
| SURMOUNT-5 [10] | 751 adults with obesity, no diabetes, 72 weeks, open-label | Weight −20.2% on tirzepatide vs −13.7% on semaglutide | Eli Lilly |
| SURMOUNT-OSA [11] | Adults with moderate to severe sleep apnea and obesity, 52 weeks | Breathing events fell 25.3 per hour vs 5.3 on placebo (no CPAP) | Eli Lilly |
| SURMOUNT-4 [12] | 670 adults who lost weight on tirzepatide for 36 weeks | Weeks 36 to 88: −5.5% if they stayed on it, +14.0% if switched to placebo | Eli Lilly (Lilly-employed authors) |
Every trial here tested Eli Lilly's drug and was run with Lilly. SURMOUNT-5 compared it with Novo Nordisk's semaglutide.
The head-to-head trial is the one people ask about. In SURMOUNT-5, tirzepatide beat semaglutide on weight and waist size at 72 weeks [10]. It was open-label and funded by Lilly, so read it as one well-run trial, not the last word. See Zepbound vs Wegovy for what that means in practice.
The sleep apnea result is just as striking. In SURMOUNT-OSA, people not using a CPAP machine saw breathing interruptions fall by 25.3 events an hour on tirzepatide vs 5.3 on placebo; in people using CPAP, the drop was 29.3 vs 5.5 [11]. Those results are what FDA based the sleep apnea approval on.
What happens when you stop Zepbound? SURMOUNT-4 is clear. After 36 weeks of treatment, people moved to placebo regained 14.0% of their weight over the next year, while those who stayed on tirzepatide lost another 5.5% [12]. For most people, Zepbound is a long-term drug or the weight comes back.
Zepbound comes as a single-dose pen, two kinds of vial and a KwikPen
Zepbound comes in four presentations, all in the same six strengths from 2.5 to 15 mg [1]. Two hold one dose. Two hold four. The difference that matters most to your wallet is where each one is sold.
| Form | Doses in each | Self-pay through LillyDirect | Extra purchase |
|---|---|---|---|
| Single-dose pen | 1 (built-in needle) | Insurance only at LillyDirect | None; needle included |
| Single-dose vial | 1 | $299 to $449 a month | Needles and syringes |
| Multi-dose vial | 4 | Not listed on LillyDirect's page | Needles and syringes |
| KwikPen (single-patient use) | 4 | $299 to $449 a month | Pen needles |
Forms from the Zepbound label; sales channels and prices from LillyDirect's Zepbound page.
Storage differs too. The label allows a single-dose pen or vial to sit unrefrigerated, at no more than 86°F, for up to 21 days in total, and it says never to use Zepbound that has frozen [1]. Ask your pharmacist how your form should be stored.
Is there a Zepbound pill? No. Zepbound is only an injection. Lilly's GLP-1 pill is Foundayo, a different molecule called orforglipron, approved in April 2026. Our Foundayo vs Zepbound comparison covers the trade-offs.
The label starts everyone at 2.5 mg and allows up to 15 mg
The Zepbound label starts every patient at 2.5 mg once a week for four weeks and says that dose “is for treatment initiation and is not approved as a maintenance dosage” [1]. The maximum is 15 mg once a week. Your prescriber sets the steps in between, based on how you're doing and how well you tolerate it.
Two things follow for cost. First, the lowest monthly price you'll see is almost always the starting dose. Second, the price usually rises after the first month. Our Zepbound dosage guide explains what the label says about each strength.
Most side effects are stomach-related, and most happen while the dose rises
Zepbound's most common side effects are gastrointestinal, and it carries the class boxed warning about thyroid C-cell tumors in rodents. In the label's pooled weight trials, stomach side effects hit 56% of people at every dose against 30% on placebo, and the label says most nausea, vomiting and diarrhea “occurred during dose escalation and decreased over time” [1].
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Hair loss | 1% | 5% | 4% | 5% |
From the pooled SURMOUNT-1 and SURMOUNT-2 data in the Zepbound label.
The label's warnings include severe stomach reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, allergic reactions, low blood sugar in people with diabetes, diabetic eye complications and aspiration during anesthesia. It also says Zepbound can make birth-control pills less reliable for a while after starting and after each dose increase, so ask your prescriber about that if it applies to you.
For the details, see Zepbound side effects, whether Zepbound causes constipation and the molecule-wide guide to tirzepatide side effects.
LillyDirect sells Zepbound for $299 to $449 a month
LillyDirect sells Zepbound vials and KwikPens for cash from $299 a month [6]. The 7.5 to 15 mg price of $449 holds only if you refill within 45 days. Miss that window and the price jumps to $499 for 7.5 mg or $699 for 10, 12.5 or 15 mg.
| Dose | Refill within 45 days | Otherwise |
|---|---|---|
| 2.5 mg (starting dose) | $299 a month | $299 a month |
| 5 mg | $399 a month | $399 a month |
| 7.5 mg | $449 a month | $499 a month |
| 10, 12.5 or 15 mg | $449 a month | $699 a month |
Source: LillyDirect Zepbound page. Vials need a separate needle and syringe purchase; KwikPens need pen needles.
With insurance, the math changes. Lilly's savings card can bring a covered single-dose pen down to $25 for up to a 3-month fill for people with commercial insurance [7]. On Medicare, CMS runs the Medicare GLP-1 Bridge, a demonstration that began July 1, 2026 with a $50 copay for eligible Part D members [8]. Lilly says Zepbound for weight management is covered there for no more than $50 a month, subject to clinical criteria [7].
For every option in one place, read our Zepbound cost guide, and use the monthly cost calculator to compare a program's billing with LillyDirect's price.
Zepbound vs Wegovy, Ozempic and Mounjaro, in brief
Zepbound and Wegovy are the two weekly brand shots labeled for weight. Zepbound produced more weight loss head to head, while Wegovy's label also covers heart-risk reduction in people with heart disease and a liver condition called MASH. Ozempic is semaglutide for type 2 diabetes, and Mounjaro is Zepbound's own molecule for type 2 diabetes. Each comparison has its own page: Zepbound vs Wegovy, Ozempic vs Zepbound and Zepbound vs Mounjaro.
Compounded tirzepatide is not Zepbound
Compounded tirzepatide is pharmacy-made, not FDA-reviewed, and now legal only in narrow, patient-specific cases. It isn't FDA-approved, FDA doesn't review it for safety or effectiveness, and FDA doesn't check its quality before it ships [5]. FDA ended the shortage that allowed mass copies in December 2024.
Because some telehealth programs still offer it for less than LillyDirect's price, it's worth knowing the difference before you compare prices. Our guides cover compounded tirzepatide vs Zepbound, whether compounded tirzepatide is still available and the compounded tirzepatide basics, and the compounded tirzepatide board scores the programs.
Microdosing Zepbound hasn't been tested
Taking less than the label's doses, often called microdosing, has not been tested in a trial, and the label calls 2.5 mg a starting dose only. Some programs market small or spaced-out doses. The evidence, and the open questions, are in our guide to microdosing tirzepatide.
You need a prescription, then LillyDirect or a pharmacy fills it
Zepbound needs a valid prescription from a licensed healthcare provider. LillyDirect says your doctor can send that prescription to LillyDirect Pharmacy, and its page also points to outside virtual care for people who don't have a prescriber [6]. Many telehealth programs prescribe the brand and send the prescription there.
Telehealth companies don't make Zepbound. They provide the visit and the prescription, and the drug comes from Lilly through a pharmacy. What you pay them on top of the medication varies a lot.
| Provider | What the monthly price covers | Monthly cost |
|---|---|---|
| AgelessRx | Membership plus LillyDirect medication | $364/mo |
| Ro | KwikPen at the maker's price plus a monthly membership | $448/mo |
| Maximus | Monthly plan; labs separate | $549.99/mo |
Prices from each provider's own site, shown as a calendar-month cost at the starting dose with required fees folded in.
Also offered by (no standing monthly price published): Sesame, Found, ShedPartner, altRx.
Research on Zepbound
Medicare and Zepbound or Wegovy: the $50 GLP-1 Bridge, explained
Since July 1, 2026, Medicare has a temporary program that covers three weight-loss GLP-1s for a flat $50 a month. Here is who qualifies, who doesn't, how to apply, and what changes for sleep apnea and diabetes.
Zepbound and tiredness: how common it is, and what drives it
Tiredness is on Zepbound's list of common side effects, though it affects far fewer people than nausea does. Here's how often it happened, what tends to travel with it, and which kinds of tiredness need a call.
Zepbound storage: the fridge, the 21-day rule and the KwikPen's 30 days
Zepbound comes in four forms, and the label gives them two different clocks once they leave the fridge. Here's which rule applies to yours, in plain numbers.
How long Zepbound stays in your body after the last dose
Zepbound is a once-a-week drug because it lingers. Here's what its half-life means in days, where the label's numbers stop and our arithmetic starts, and how it compares with semaglutide.
Does Zepbound cause constipation? Its stomach side effects, by dose
Constipation, nausea and diarrhea are the side effects people notice most on Zepbound. Here’s how often each one showed up in the trials, at each dose, when they tend to ease, and which symptoms mean you should call.
How much is Zepbound? Every price, with and without insurance
Most people pay one of four prices for Zepbound: the savings-card copay, LillyDirect’s self-pay price, Medicare’s new GLP-1 Bridge copay, or the list price. Which one applies to you depends on your coverage, your dose and how fast you refill.
Zepbound doses: the 2.5 mg start, the maintenance doses and the 15 mg maximum
Zepbound's label names one starting dose, a short list of maintenance doses and one maximum. Here's what each one is for, what the SURMOUNT trials found at each, and what your prescriber decides.
Zepbound side effects: the full list, and how long they last
Most Zepbound side effects are digestive, and they follow the dose: they tend to show up when it goes up and fade in the weeks after. Here's the label's full list by dose, the serious warnings with their warning signs, and the symptoms people ask about that the label doesn't mention.
Zepbound compared
Compounded tirzepatide vs Zepbound: what's the same and what isn't
Both contain tirzepatide. Only one has an FDA approval, a tested device and trial results behind it. Here is the comparison, row by row, with current prices.
Is Foundayo as effective as Zepbound? What the trials show
Both come from Eli Lilly, but they're different molecules in different forms. Zepbound produced about twice the average weight loss in its trial. Foundayo costs less, is a pill with no food rules, and may help hold on to weight lost on an injection.
Is Zepbound the same as Ozempic? No, and here's how they differ
Different molecules, different makers and different approved uses. The quickest way to compare them is to see which drug each one is really paired with.
Is Zepbound the same as Mounjaro? Yes and no
Same molecule, same maker, same strengths. What changes is the diagnosis each one is approved for, and that's what sets your price.
Zepbound or Wegovy: which weight-loss label fits you
The two drugs approved for weight management, compared on what they did head to head, what else each is approved for, and what each costs without insurance.
Compare providers
Providers that offer Zepbound
- Maximus review →
Maximus
You want a brand GLP-1 pill such as Foundayo or Wegovy tablets at a printed cash price, from a provider that names its pharmacies.
- AgelessRx review →
AgelessRx
You want a longevity-focused program for rapamycin or metformin with labs built in, or brand Wegovy pill access with a clear monthly total.
- Ro review →
Ro
You want an FDA-approved GLP-1, such as the Wegovy pill, Foundayo or Zepbound, at a published cash price for each dose, or help getting a pen covered by insurance.
- Heally review →
Heally
You want to talk through off-label rapamycin or metformin with a physician in a live visit, with the medication and visit bundled at a printed monthly price.
- MEDGm review →Visit site →
MEDGmPartner
You want labs, clinician visits, side-effect medicine and shipping in one monthly price that holds at every dose, from a program that names its pharmacies.
See all 21 providers on the brand Wegovy and Zepbound lineup →
Frequently asked
- Is Zepbound for diabetes or weight loss?
- Weight loss and sleep apnea. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Mounjaro, the same drug, is the brand approved for type 2 diabetes.
- Is there a Zepbound pill?
- No. Zepbound is only a weekly injection. Lilly's GLP-1 pill is Foundayo, which contains a different drug, orforglipron.
- Is Zepbound the same as Mounjaro?
- They contain the same drug, tirzepatide, made by the same company. The labels differ: Zepbound is for weight and sleep apnea, Mounjaro for type 2 diabetes. That changes insurance coverage and the self-pay price.
- How much weight do people lose on Zepbound?
- In SURMOUNT-1, the average was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% on placebo. Those are trial averages; results vary from person to person.
- Can you buy Zepbound without insurance?
- Yes, with a prescription. LillyDirect sells vials and KwikPens for cash, from $299 a month at the starting dose to $449 at higher doses if you refill within 45 days.
- What happens when you stop Zepbound?
- Most people regain weight. In SURMOUNT-4, people switched to placebo after 36 weeks regained 14.0% of their body weight over the next year, while those who kept taking it lost another 5.5%.
Sources
- [1] Zepbound (tirzepatide) injection, prescribing information (2026). DailyMed label
- [2] FDA approves new medication for chronic weight management (2023). FDA
- [3] FDA approves first medication for obstructive sleep apnea (2024). FDA
- [4] Zepbound supplement approval letter S-041 (2026). FDA
- [5] FDA's concerns with unapproved GLP-1 drugs used for weight loss (2026). FDA
- [6] LillyDirect: Zepbound self-pay pricing (2026). Company website
- [7] Zepbound savings and coverage options (2026). Company website
- [8] CMS: Medicare GLP-1 Bridge (2026). Source
- [9] Jastreboff AM. Tirzepatide Once Weekly for the Treatment of Obesity (2022). PMID 35658024
- [10] Aronne LJ. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025). PMID 40353578
- [11] Malhotra A. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024). PMID 38912654
- [12] Aronne LJ. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024). PMID 38078870
- [13] Nicholls SJ. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (2025). PMID 41406444